GlassScriptPhysician profile
William M Carrera
NPI 1679014013
$8,475.96
in general payments reported to CMS, 2019-2025
9 companies · $6,637 in 2025
The $6,637 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $218 · 2023: $1,101 · 2024: $521 · 2025: $6,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,655 · Food and Beverage: $2,098 · Travel and Lodging: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,655.00 |
| Food and Beverage | $2,097.72 |
| Travel and Lodging | $505.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $6,862.44 | 2023-2025 | Vabysmo |
| Alcon Vision LLC | $601.89 | 2022-2023 | Constellation, Ngenuity |
| Regeneron Pharmaceuticals, INC. | $363.52 | 2023-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $270.00 | 2022-2024 | Syfovre |
| Abbvie INC. | $116.98 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $112.46 | 2022 | |
| Ani Pharmaceuticals, INC. | $56.67 | 2024-2025 | Yutiq, Purified Cortrophin Gel |
| Astellas Pharma US INC | $50.97 | 2024-2025 | Izervay |
| Alimera Sciences, INC. | $41.03 | 2024 | Yutiq, Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Carrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.